Is Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20?

Published on January 12, 2025 at 9:35 am by Ali Ahmed in News

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against the other best medical stocks under $20.

The medical industry plays a crucial role in ensuring the health and safety of populations. Driven by advancements in medical technology and an aging population, the medical and healthcare industry is expected to grow significantly in the coming years.

According to Deloitte’s 2024 Global Healthcare Sector Outlook, the use of technologies like artificial intelligence (AI) is rising in the healthcare sector. Healthcare providers and technology companies are introducing various kinds of AI tools that can help improve clinical outcomes. These technological advancements can streamline various administrative tasks while also enhancing the quality of care provided to patients.

Healthcare in the US

In the US, healthcare costs and spending have been rising. As reported by the Centers for Medicare & Medicaid Services, healthcare spending in the United States reached $4.9 trillion in 2023, reflecting a 7.5% increase from 2022. In 2023, the healthcare sector accounted for 17.6% of the US economy in 2023, up from 17.4% in 2022. Rise in private health insurance and Medicare were the two main drivers of this growth.

Donald Trump nominated Robert F. Kennedy Jr. to serve as the next Secretary of Health and Human Services, a role that covers various aspects of public health, including medical research and food safety. If confirmed, Kennedy would oversee key agencies like the US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) and the head of the Centers for Medicare and Medicaid Services (CMS). In an NPR interview in November, Kennedy said that Trump had tasked him with eliminating corruption in health agencies, restoring evidence-based practices, and addressing the chronic disease epidemic. It’s not clear how Kennedy’s nomination could impact the healthcare sector as his specific policies are not yet clear and he has yet to receive confirmation by the US Senate.

Chris Schott, JPMorgan’s healthcare analyst, pointed out in a note to clients that the industry is currently experiencing “a period of max uncertainty” until the position is filled. However, Schott noted that this situation also means that the large-cap stocks are currently trading at a 35% discount to the S&P 500, presenting a significant opportunity for growth.

Jared Holz, Mizuho’s healthcare expert, said in a note to clients that he acknowledges some of Kennedy’s concerns, such as America’s obesity epidemic and the risks associated with ultra-processed foods. Holz noted that this is a complicated topic but emphasized that there is substantial room for improvement in public health.

However, Kennedy is known as an anti-vaxxer and this has concerned some Wall Street analysts about his possible effect on the vaccine industry. He has also expressed skepticism about GLP-1s, which he believes are not the solution to the obesity problem. Additionally, Kennedy has advocated for stricter regulations on ultra-processed foods, which are linked to rising obesity rates in the country.

Methodology

To compile our list of the 12 best medical stocks to buy under $20, we used the Finviz stock screener. We sorted our results based on market capitalization and picked the top 30 medical companies with a share price of under $20 as of January 8, 2024. Next, we focused on the top 12 stocks most favored by institutional investors. Data for the hedge fund sentiment surrounding each stock was taken from Insider Monkey’s Q3 2024 database of 900 elite hedge funds. The 12 best medical stocks to invest in were then ranked in ascending order based on the number of hedge funds holding stakes in them as of Q3 2024.

Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Doctors in a lab coat attending to a patient receiving enzyme replacement therapies.

Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Share Price as of January 8: $9.46

Number of Hedge Fund Holders: 38

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is an American biopharmaceutical company that specializes in developing and commercializing innovative treatments for rare diseases. The company’s primary focus is on orphan diseases, which often lack effective therapies, making its work vital for patients in need.

The company’s strategic focus on rare diseases positions it favorably within the medical market. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is advancing its work to establish leadership in treating both Fabry and Pompe diseases. The company has managed to significantly increase its revenues with a strong commitment to innovation and patient care.

In the third quarter of 2024, Amicus Therapeutics, Inc. (NASDAQ:FOLD) reported total revenues of $141.5 million, marking a 37% increase year-over-year. The revenue from the company’s flagship product, Galafold, reached $120.4 million, up 20% compared to the previous year. Galafold is an oral treatment for Fabry disease that stabilizes a dysfunctional enzyme in patients with specific genetic variants. This product has demonstrated strong demand and market presence. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has also recently launched Pombiliti and Opfolda, a two-component therapy for Pompe disease, which generated $21.1 million in revenue during Q3 2024. This marks a 33% increase from the second quarter of 2024.

Overall, FOLD ranks 5th on our list of the best medical stocks to buy under $20. While we acknowledge the potential of FOLD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than FOLD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

Disclosure: None. This article is originally published at Insider Monkey.

Yahoo Finance

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on November 14, 2025 at by Inan Dogan, PhD

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up